A large new study suggests that one of the world’s most widely prescribed classes of antidepressants may do far more than lift mood. Researchers report that patients with solid tumors who were taking selective serotonin reuptake inhibitors, or SSRIs, while receiving immune checkpoint inhibitors survived substantially longer than comparable patients taking benzodiazepines instead. The findings, published in PLOS Medicine, offer the strongest clinical signal yet that a decades-old psychiatric medication could be repurposed as an ally in cancer immunotherapy, and they arrive with a layer of transcriptomic evidence that hints at why the effect might be real rather than statistical noise.
Immune checkpoint inhibitors have transformed the treatment of many advanced cancers by releasing the molecular brakes that tumors place on T cells, the immune system’s cytotoxic foot soldiers. Yet most patients still do not respond durably, and researchers have spent years searching for affordable, safely tolerated drugs that could widen the benefit. SSRIs have emerged as an intriguing candidate. Preclinical work has identified the serotonin transporter, the protein these drugs block, as a kind of immune checkpoint in its own right on CD8-positive T cells. When that transporter, encoded by the gene SLC6A4, is active on T cells, serotonin uptake appears to dampen their antitumor activity. Blocking it with SSRIs, laboratory studies indicate, can reinvigorate these cells and act in synergy with anti-PD-1 therapy, the backbone of modern immunotherapy.
What has been missing is human evidence at scale. The new research, led by Po-Huang Chen and colleagues, addressed that gap using a target trial emulation, a modern epidemiological design that mimics the logic of a randomized clinical trial using real-world medical records. The team mined the TriNetX federated electronic health record network, which aggregates data on more than 187 million patients, to assemble a study population of adults with a solid tumor who began an immune checkpoint inhibitor between 2015 and 2025 and who had a diagnosed depressive or anxiety disorder in the preceding year. Because depression itself influences cancer outcomes, the investigators needed a comparison group of patients with similar psychiatric burden but without SSRI exposure, and they settled on patients receiving benzodiazepines, another common class of psychiatric medications.
The design was deliberately strict. Exposure required an active SSRI or benzodiazepine prescription overlapping the date of the first immunotherapy infusion or beginning within the previous 90 days. The primary endpoint was overall survival at two years, and the researchers prespecified twenty secondary outcomes organized across four mechanistic pathways, an unusually disciplined approach intended to prevent cherry-picking of favorable results. Propensity score matching on 49 baseline characteristics, spanning demographics, comorbidities, medications, and healthcare utilization, produced 1,567 well-balanced pairs, or 3,134 patients in total, giving the analysis substantial statistical power.
The survival difference was striking. Two-year all-cause mortality was 23.5 percent among SSRI users compared with 34.4 percent among benzodiazepine users, corresponding to a hazard ratio of 0.627 with a 95 percent confidence interval of 0.549 to 0.716 and a p value below 0.001. In practical terms, patients on SSRIs were roughly 37 percent less likely to die over the two-year window. The strength of the association was robust enough that the authors calculated an E-value of 2.57, meaning an unmeasured confounder would need to be associated with both treatment and survival by a factor of more than two and a half to explain away the result entirely.
Notably, the mortality benefit was not confined to a single drug. All five SSRIs with enough users for individual analysis, including agents such as sertraline, escitalopram, and paroxetine, showed lower mortality, with hazard ratios ranging from 0.61 to 0.71. This consistency across chemically distinct molecules within the class argues against a drug-specific artifact and supports the idea that the shared mechanism, serotonin transporter blockade, is what matters. The researchers also observed that newly coded distant metastases were significantly less frequent in the SSRI group, with a hazard ratio of 0.629, suggesting the antidepressants may have slowed cancer’s spread rather than merely improving general health.
If SSRIs genuinely amplify immunotherapy, the immune system should show fingerprints of heightened activity, and it did. Composite immune-related adverse events, the inflammatory side effects that arise when unleashed T cells attack healthy tissue, were modestly more frequent among SSRI users, with a hazard ratio of 1.162. The increase was driven almost entirely by thyroid dysfunction, which showed a hazard ratio of 1.199, while rates of hepatitis, pneumonitis, and colitis were unchanged. Even more telling were the negative controls. Three prespecified conditions with no plausible immunologic connection to serotonin signaling, namely nephrolithiasis, cholelithiasis, and cataract, showed completely null associations, all with p values above 0.76. That pattern of organ-selective immune activation, rather than indiscriminate inflammation, is exactly what a true biological effect would be expected to produce.
The transcriptomic arm of the study added a second, independent line of evidence. Analyzing 8,272 tumor samples from 8,172 patients across 20 cancer types in The Cancer Genome Atlas, the researchers examined how SLC6A4 expression related to tumor immune-cell infiltration. In 13 of the 20 cancer types, higher expression of the serotonin transporter gene was inversely correlated with T-cell inflammation, meaning tumors that expressed more of the transporter tended to be more immunologically cold. Crucially, this organ-level pattern mirrored the organ distribution of immune-related adverse events seen in the clinical cohort, linking the pharmacology of serotonin reuptake to immune behavior across tissues in a way the authors describe as biologically coherent.
The investigators are careful to flag the study’s central limitation: residual confounding. Performance status, the clinician’s rating of a patient’s everyday functional ability that strongly predicts cancer survival, is not systematically recorded in the electronic health record network. Benzodiazepines and SSRIs are also prescribed in different clinical circumstances, so even after matching on 49 covariates, the two groups may differ in subtle ways that bias the comparison. The TCGA analyses carry their own constraints, since they used bulk tumor tissue from patients who were never treated with immunotherapy and therefore cannot localize serotonin transporter expression to specific cell types or prove that SSRIs remodel the tumor microenvironment in living patients.
Even with those caveats, the convergence of evidence is unusual and compelling. A rigorously emulated trial showing lower mortality, reduced metastatic spread, organ-selective immune activation, and null results on negative controls, all corroborated by an independent transcriptomic dataset, is precisely the profile that repurposing advocates look for before investing in prospective testing. The authors conclude that the findings warrant formal prospective evaluation of SSRIs as an adjuvant to immune checkpoint blockade, and the implications are tantalizing: if randomized trials confirm the signal, a cheap, generic, globally available class of antidepressants could extend the reach of cancer immunotherapy to millions of patients who currently derive little benefit from it. For now, the message for patients is not to start or change medications on their own, but the scientific message is clear: the serotonin system has earned a place on oncology’s research agenda.
Subject of Research: Repurposing of selective serotonin reuptake inhibitors as adjuvants to immune checkpoint blockade in solid tumor cancer treatment
Article Title: Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses
Article References: Chen, P.-H., Dai, M.-S., Huang, M.-H., Chen, H.-Y., Kao, L.-T., Hsieh, T. Y.-J., Jhou, H.-J., & Lee, C.-H. (2026). Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses. PLOS Medicine, 23(9), e1005262. https://doi.org/10.1371/journal.pmed.1005262
Image Credits: AI Generated
DOI: 10.1371/journal.pmed.1005262
Keywords: SSRIs, immune checkpoint inhibitors, serotonin transporter, SLC6A4, cancer immunotherapy, target trial emulation, overall survival, immune-related adverse events, The Cancer Genome Atlas, drug repurposing, CD8 T cells, solid tumors
News Source: Nathaniel Bowman. (October 9, 2026). Common Antidepressants May Boost Immunotherapy Survival in Cancer Patients, Major Study Finds. Scienmag.
